Ignite Creation Date:
2024-05-06 @ 5:59 PM
Last Modification Date:
2024-10-26 @ 2:39 PM
Study NCT ID:
NCT05509478
Status:
UNKNOWN
Last Update Posted:
2022-09-10
First Post:
2022-08-18
Brief Title:
Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for UnresectableAdvanced Biliary Tract Carcinoma
Sponsor:
The First Hospital of Jilin University
Organization:
The First Hospital of Jilin University
Organization Data
Organization:
The First Hospital of Jilin University
Class:
OTHER
Study ID:
FirstJlinU
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
The First Hospital of Jilin University
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None